$OESX

Orion Energy Targets $95M-$97M Revenue After Margin Gains at Annual Meeting

Orion Energy Systems (NASDAQ:OESX) reported FY2026 revenue targets of $95M to $97M and expects positive adjusted EBITDA for the year, after margin gains at its annual meeting. LED lighting revenue rose to $55.9M from $47.7M, with gross margin up to 33.8%. EV charging revenue fell to $14.4M from $16.8M, while maintenance revenue rose to $16.0M.

Original reporting
Published Aug 8, 2026, 2:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 8, 2026, 2:39 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Orion Energy Targets $95M-$97M Revenue After Margin Gains at Annual Meeting — source image
Decision brief

The 30-second read

$OESXBullishMed
01

Why it matters

Management highlighted LED lighting margin expansion from price increases, cost reductions, and sourcing initiatives, while EV charging faced a changed market environment. The company’s FY2027 revenue target ($95M-$97M) and expectation of positive adjusted EBITDA are the key decision inputs for traders.

02

Market read

Traders can update positioning based on the new FY2027 revenue range and profitability expectation, plus the stated drivers (LED margin gains, maintenance pricing/restructuring, and data-center expansion).

03

What to watch

Upside depends on customer infrastructure investment levels, which are not quantified; investors may discount guidance if data-center engagement timing or EV charging normalization is slower than expected.

Relevance 7/10Novelty 7/10Timing: ahead of FY2027 planning, post-annual meeting outlook

Background

Orion Energy Systems discussed segment performance (LED lighting, EV charging solutions, maintenance services) and presented an FY2027 outlook at its annual meeting.

Company-level read

Ticker impact

$OESXBullishMedium confidence
Context

Orion Energy Systems guided FY2027 revenue to $95M-$97M and expects positive adjusted EBITDA, citing margin gains and potential upside from customer infrastructure spend.

Expected impact

Moderate upside bias for near-term trading as the guidance range and positive adjusted EBITDA expectation can re-rate the stock, especially if investors focus on data-center and infrastructure capex.

Evidence & confidence

This is a primary management outlook update with specific numbers and segment margin improvements, but it is not an earnings print with actual results or a balance-sheet financing event.

Market effects

Could support sentiment for energy-efficient lighting and EV charging infrastructure suppliers by reinforcing that LED margin expansion and data-center demand are key drivers.

Primarily US-focused narrative given the EV charging market reset and hyperscale data-center engagement.

Limited direct global read-through; mostly US infrastructure and commercial/industrial lighting demand.

Counterpoint

EV charging revenue declined year over year, so the FY2027 range may rely heavily on LED and maintenance recovery rather than a durable EV charging rebound.

Key entities

  • Orion Energy Systems

    Provider of LED lighting and building controls solutions; issued FY2027 revenue guidance and discussed segment margin drivers.

Related articles

$OESXMedAI 8/10

Orion Energy Systems (OESX) Q1 2027 Earnings Call Transcript

Orion Energy Systems (OESX) reported fiscal 2027 Q1 revenue of $25.7 million, up 32% year over year, driven by 37% higher LED lighting sales to $17.7 million. Net income was $2 million ($0.47 diluted). Adjusted EBITDA was $2.5 million. The company guided FY2027 revenue to $95 million to $97 million and cited a $24 million backlog.

$OESXMedAI 8/10

Orion Energy Systems Reports 32% Revenue Growth as Return to Profit Supports Fiscal 2027 Outlook

Orion Energy Systems (NASDAQ:OESX) reported fiscal Q1 2027 revenue up 32% to $25.7 million, driven by LED lighting and EV charging. Net income returned to $2.0 million versus a $1.2 million loss a year earlier. Gross margin rose 450 bps to 34.6% and adjusted EBITDA stayed positive at $2.5 million. Company reaffirmed FY2027 revenue guidance of $95 million to $97 million and expects full-year positive adjusted EBITDA.

$OESXMed

ORION ENERGY SYSTEMS, INC. (OESX): Results of Operations and Financial Condition

ORION ENERGY SYSTEMS, INC. (OESX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Orion Reports First Quarter Financial Results: Revenue Increases 32% to 25.7M, Net Income at $2M Manitowoc, WI – August 5, 2026 – Orion Energy Systems, Inc. (NASDAQ: OESX) ( Orion Lighting ), a provider of energy-efficient LED lighting, electric vehicle (EV) charging stations and

$OESXMedAI 9/10

Orion (OESX) Q4 2026 Earnings Transcript

Orion Energy Systems (OESX) reported fiscal 2026 revenue of $86.3 million (up from $79.7 million) and positive adjusted EBITDA of $2.2 million (vs. -$2.9 million in 2025). Net loss narrowed to $3.2 million ($0.89/share). Q4 revenue rose to $25.7 million. The company guided FY2027 revenue of $95–$97 million and said it exited its remaining solar contract.

$OESXMedAI 9/10

Orion Reports FY 2026 Revenue of $86M and Adjusted EBITDA of $2.2M After Continued Growth in Q4; Reiterates FY 2027 Expectation of $95M-$97M in Revenue and Positive Adjusted EBITDA

Orion Energy Systems (OESX) reported FY2026 revenue of $86.3M (up from $79.7M) and adjusted EBITDA of $2.2M, after a FY2025 adjusted EBITDA loss of $2.9M, according to the company. Q4 revenue rose to $25.7M and adjusted EBITDA to $0.8M. Orion reiterated FY2027 revenue guidance of $95M–$97M with positive adjusted EBITDA.

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.